Celcuity Net Profit Margin 2016-2024 | CELC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Celcuity net profit margin from 2016 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Celcuity net profit margin from 2016 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$119.5B
Regeneron Pharmaceuticals (REGN)	$114.6B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$101.6B
CSL (CSLLY)	$97.4B
GSK (GSK)	$84.8B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.4B
Biogen (BIIB)	$28.2B
BioNTech SE (BNTX)	$28B
Moderna (MRNA)	$24.6B
Illumina (ILMN)	$21.1B
BeiGene (BGNE)	$20.7B
Genmab (GMAB)	$16B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.6B
Incyte (INCY)	$12.5B
Insmed (INSM)	$12.5B
Vaxcyte (PCVX)	$12.4B
Bio-Techne Corp (TECH)	$12.4B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Ascendis Pharma (ASND)	$8.6B
Roivant Sciences (ROIV)	$8.6B
Legend Biotech (LEGN)	$8.5B
Repligen (RGEN)	$8.2B
Intra-Cellular Therapies (ITCI)	$7.7B
Exelixis (EXEL)	$7.5B